Global Biologics Outsourcing Market - 2025 -2033
Global Biologics Outsourcing Market: Industry Outlook
The global biologics outsourcing market reached US$ 20.10 billion in 2023, with a rise of US$ 22.92 billion in 2024, and is expected to reach US$ 64.57 billion by 2033, growing at a CAGR of 12.1% during the forecast period 2025-2033.
The biologics outsourcing market is experiencing steady growth, driven by the increasing complexity of biologic drugs, the expansion of biosimilars, and the rising demand for cost-efficient, specialized manufacturing capabilities. Contract development and manufacturing organizations (CDMOs) are becoming integral partners as pharmaceutical companies seek to accelerate pipelines, reduce capital investment, and leverage advanced technologies such as single-use bioreactors and continuous manufacturing. Monoclonal antibodies and oncology biologics remain the largest contributors, while emerging modalities.
At the same time, the global push for biosimilars is driving large-scale production and analytical support, particularly in regions such as North America, Europe, and the fast-growing Asia-Pacific markets. As regulatory expectations evolve and digital innovations improve efficiency and quality control, biologics outsourcing is positioning itself as a critical growth engine for the life sciences industry, offering end-to-end solutions that enhance speed-to-market, resilience, and patient access worldwide.
Dynamics: Drivers & Restraints
Driver: Expanding Biologics Pipeline
The accelerating expansion of the global biologics pipeline, with over 6,000 active drug candidates in development as of 2021, underpins robust demand for outsourcing to specialized CDMOs and CMOs. This surge encompasses advanced biologic modalities like monoclonal antibodies, bispecifics, cell and gene therapies, and ADCs, all requiring complex manufacturing, analytical capabilities, and stringent regulatory compliance.
Outsourcing partners not only enable sponsors to scale rapidly and deploy advanced technologies but also deliver strategic agility, reducing capital commitments while meeting the growing volume, diversity, and technical demands of biologic R&D. In this way, the expanding biologics pipeline directly fuels the growth of the biologics outsourcing market by creating sustained, high-complexity manufacturing needs.
Restraint: Supply-chain/Geopolitical Risks
The biologics outsourcing market faces mounting challenges from supply-chain disruptions and geopolitical risks, which threaten reliability, cost structures, and long-term strategic planning. Heavy dependence on globalized networks has exposed vulnerabilities, with events such as pandemic-era shortages, trade restrictions, and the U.S. Biosecure Act intensifying scrutiny. Rising geopolitical tensions are pushing pharma companies to diversify or “de-risk” supply chains by shifting production to domestic or regional CDMOs, but such transitions add complexity, regulatory hurdles, and higher operational costs. These risks can lead to delays in drug development and commercialization, reduced flexibility for sponsors, and pricing pressures on CDMOs.
Segment Analysis
The global biologics outsourcing market is segmented based on service type, product, process stage, source, outsourcing model end-user, and region.
Service Type:
The process development segment is estimated to have 42.8% of the biologics outsourcing market share.
The process development segment is emerging as the backbone of the biologics outsourcing market because it provides the essential bridge between early-stage discovery and full-scale manufacturing. With biologics becoming increasingly complex, companies are relying heavily on CDMOs to design, optimize, and validate robust upstream and downstream processes. Effective process development ensures scalability, regulatory compliance, and cost efficiency, while reducing risks during technology transfer and commercial production.
As pharmaceutical companies prioritize speed-to-market and asset-light strategies, the demand for specialized process development services is expected to dominate outsourcing partnerships, reinforcing this segment’s central role in driving market growth. Furthermore, advancements in single-use technologies, high-throughput process optimization, and digital bioprocessing tools are expanding CDMOs’ capabilities, enabling faster development timelines and more reliable outcomes. The increasing emphasis on quality by design (QbD) and regulatory expectations for well-characterized processes further amplify the importance of process development as the cornerstone of biologics outsourcing.
Geographical Share Analysis
The North America biologics outsourcing market was valued at 42.1% market share in 2024
North America is dominating the biologics outsourcing market due to its well-established biopharmaceutical ecosystem, strong presence of leading CDMOs, and continuous investment in advanced manufacturing capabilities. The region benefits from a large pipeline of biologics and biosimilars, particularly in oncology and immunology, supported by a highly skilled workforce and strong regulatory frameworks such as the FDA’s robust oversight of biologics manufacturing. Major pharmaceutical companies headquartered in the U.S. increasingly rely on outsourcing to accelerate development and reduce costs, while CDMOs in the region continue to expand facilities, adopt cutting-edge technologies like single-use systems and continuous bioprocessing, and integrate digital and AI-driven process optimization.
Additionally, the rising trend of nearshoring to strengthen supply-chain resilience further reinforces North America’s leadership, making it the hub for innovation, quality, and large-scale biologics production in the global outsourcing landscape.
Competitive Landscape
The major players in the biologics outsourcing market include AbbVie Inc., Boehringer Ingelheim International GmbH, Catalent, Inc. (Novonordisk), Charles River Laboratories, WuXi Biologics, CordenPharma, Rentschler Biopharma SE, Syngene International Limited, among others.
Key Developments
The global biologics outsourcing market reached US$ 20.10 billion in 2023, with a rise of US$ 22.92 billion in 2024, and is expected to reach US$ 64.57 billion by 2033, growing at a CAGR of 12.1% during the forecast period 2025-2033.
The biologics outsourcing market is experiencing steady growth, driven by the increasing complexity of biologic drugs, the expansion of biosimilars, and the rising demand for cost-efficient, specialized manufacturing capabilities. Contract development and manufacturing organizations (CDMOs) are becoming integral partners as pharmaceutical companies seek to accelerate pipelines, reduce capital investment, and leverage advanced technologies such as single-use bioreactors and continuous manufacturing. Monoclonal antibodies and oncology biologics remain the largest contributors, while emerging modalities.
At the same time, the global push for biosimilars is driving large-scale production and analytical support, particularly in regions such as North America, Europe, and the fast-growing Asia-Pacific markets. As regulatory expectations evolve and digital innovations improve efficiency and quality control, biologics outsourcing is positioning itself as a critical growth engine for the life sciences industry, offering end-to-end solutions that enhance speed-to-market, resilience, and patient access worldwide.
Dynamics: Drivers & Restraints
Driver: Expanding Biologics Pipeline
The accelerating expansion of the global biologics pipeline, with over 6,000 active drug candidates in development as of 2021, underpins robust demand for outsourcing to specialized CDMOs and CMOs. This surge encompasses advanced biologic modalities like monoclonal antibodies, bispecifics, cell and gene therapies, and ADCs, all requiring complex manufacturing, analytical capabilities, and stringent regulatory compliance.
Outsourcing partners not only enable sponsors to scale rapidly and deploy advanced technologies but also deliver strategic agility, reducing capital commitments while meeting the growing volume, diversity, and technical demands of biologic R&D. In this way, the expanding biologics pipeline directly fuels the growth of the biologics outsourcing market by creating sustained, high-complexity manufacturing needs.
Restraint: Supply-chain/Geopolitical Risks
The biologics outsourcing market faces mounting challenges from supply-chain disruptions and geopolitical risks, which threaten reliability, cost structures, and long-term strategic planning. Heavy dependence on globalized networks has exposed vulnerabilities, with events such as pandemic-era shortages, trade restrictions, and the U.S. Biosecure Act intensifying scrutiny. Rising geopolitical tensions are pushing pharma companies to diversify or “de-risk” supply chains by shifting production to domestic or regional CDMOs, but such transitions add complexity, regulatory hurdles, and higher operational costs. These risks can lead to delays in drug development and commercialization, reduced flexibility for sponsors, and pricing pressures on CDMOs.
Segment Analysis
The global biologics outsourcing market is segmented based on service type, product, process stage, source, outsourcing model end-user, and region.
Service Type:
The process development segment is estimated to have 42.8% of the biologics outsourcing market share.
The process development segment is emerging as the backbone of the biologics outsourcing market because it provides the essential bridge between early-stage discovery and full-scale manufacturing. With biologics becoming increasingly complex, companies are relying heavily on CDMOs to design, optimize, and validate robust upstream and downstream processes. Effective process development ensures scalability, regulatory compliance, and cost efficiency, while reducing risks during technology transfer and commercial production.
As pharmaceutical companies prioritize speed-to-market and asset-light strategies, the demand for specialized process development services is expected to dominate outsourcing partnerships, reinforcing this segment’s central role in driving market growth. Furthermore, advancements in single-use technologies, high-throughput process optimization, and digital bioprocessing tools are expanding CDMOs’ capabilities, enabling faster development timelines and more reliable outcomes. The increasing emphasis on quality by design (QbD) and regulatory expectations for well-characterized processes further amplify the importance of process development as the cornerstone of biologics outsourcing.
Geographical Share Analysis
The North America biologics outsourcing market was valued at 42.1% market share in 2024
North America is dominating the biologics outsourcing market due to its well-established biopharmaceutical ecosystem, strong presence of leading CDMOs, and continuous investment in advanced manufacturing capabilities. The region benefits from a large pipeline of biologics and biosimilars, particularly in oncology and immunology, supported by a highly skilled workforce and strong regulatory frameworks such as the FDA’s robust oversight of biologics manufacturing. Major pharmaceutical companies headquartered in the U.S. increasingly rely on outsourcing to accelerate development and reduce costs, while CDMOs in the region continue to expand facilities, adopt cutting-edge technologies like single-use systems and continuous bioprocessing, and integrate digital and AI-driven process optimization.
Additionally, the rising trend of nearshoring to strengthen supply-chain resilience further reinforces North America’s leadership, making it the hub for innovation, quality, and large-scale biologics production in the global outsourcing landscape.
Competitive Landscape
The major players in the biologics outsourcing market include AbbVie Inc., Boehringer Ingelheim International GmbH, Catalent, Inc. (Novonordisk), Charles River Laboratories, WuXi Biologics, CordenPharma, Rentschler Biopharma SE, Syngene International Limited, among others.
Key Developments
- In June 2024, Aurigene Pharmaceutical Services inaugurated a state-of-the-art biologics facility in Hyderabad, spanning 70,000 square feet. The new center is designed to provide comprehensive process and analytical development services, along with small-scale manufacturing of antibodies and recombinant proteins. With a focus on supporting preclinical studies and early-phase clinical trials, the facility strengthens Aurigene’s capabilities in advancing innovative biologics from development to the clinic.
- In October 2023, Tanvex BioPharma USA Inc. launched Tanvex CDMO to provide comprehensive biologic contract development and manufacturing services, offering its experience and expertise to the biopharmaceutical industry.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Service Type
2.4. Snippet by Product
2.5. Snippet by Process Stage
2.6. Snippet by Source
2.7. Snippet by Outsourcing Model
2.8. Snippet by End-User
2.9. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Expanding Biologics Pipeline
3.1.1.2. CDMO Strategy & Expansion
3.1.2. Restraints
3.1.2.1. Supply-chain/Geopolitical Risks
3.1.2.2. Regulatory & Compliance Complexity
3.1.3. Opportunity
3.1.3.1. Biosimilars Manufacturing Services
3.1.3.2. Regional Expansion
3.1.4. Impact Analysis
4. GLOBAL BIOLOGICS OUTSOURCING MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY SERVICE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
5.1.2. Market Attractiveness Index, By Service Type
5.2. Process Development*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Cell Development
5.4. Analytical Services
5.5. Others
6. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY PRODUCT
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
6.1.2. Market Attractiveness Index, By Product
6.2. Antibodies*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Vaccines
6.4. Cell and Gene Therapies
6.5. Recombinant Proteins
6.6. Others
7. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY PROCESS STAGE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
7.1.2. Market Attractiveness Index, By Process Stage
7.2. Clinical*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Phase I
7.2.4. Phase II
7.2.5. Phase III
7.3. Commercial
7.4. Research
8. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY SOURCE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
8.1.2. Market Attractiveness Index, By Source
8.2. Mammalian*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Microorganisms
9. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY OUTSOURCING MODEL
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
9.1.2. Market Attractiveness Index, By Outsourcing Model
9.2. CDMO*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. CMO
9.4. CRO
10. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Biotech Companies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Pharmaceutical Companies
10.4. Research Organizations
10.5. Others
11. GLOBAL BIOLOGICS OUTSOURCING MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.9.1. U.S.
11.2.9.2. Canada
11.2.9.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.9.1. Germany
11.3.9.2. U.K.
11.3.9.3. France
11.3.9.4. Spain
11.3.9.5. Italy
11.3.9.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.9.1. Brazil
11.4.9.2. Argentina
11.4.9.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.9.1. China
11.5.9.2. India
11.5.9.3. Japan
11.5.9.4. South Korea
11.5.9.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
12.1. Competitive Overview and Key Market Players
12.2. Market Share Analysis and Positioning Matrix
12.3. Strategic Partnerships, Mergers & Acquisitions
12.4. Key Developments in Product Portfolios and Innovations
12.5. Company Benchmarking
13. COMPANY PROFILES
13.1. AbbVie Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.2.1. Product Description
13.1.2.2. Product Key Performance Indicators (KPIs)
13.1.2.3. Historic and Forecasted Product Sales
13.1.2.4. Product Sales Volume
13.1.3. Financial Overview
13.1.3.1. Company Revenue
13.1.3.2. Geographical Revenue Shares
13.1.3.3. Revenue Forecasts
13.1.4. Key Developments
13.1.4.1. Mergers & Acquisitions
13.1.4.2. Key Product Development Activities
13.1.4.3. Regulatory Approvals, etc.
13.1.4.4. SWOT Analysis
13.2. Boehringer Ingelheim International GmbH
13.3. Catalent, Inc
13.4. Charles River Laboratories
13.5. WuXi Biologics
13.6. CordenPharma
13.7. Rentschler Biopharma SE
13.8. Syngene International Limited (LIST NOT EXHAUSTIVE)
14. ASSUMPTIONS AND RESEARCH METHODOLOGY
14.1. Data Collection Methods
14.2. Data Triangulation
14.3. Forecasting Techniques
14.4. Data Verification and Validation
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Service Type
2.4. Snippet by Product
2.5. Snippet by Process Stage
2.6. Snippet by Source
2.7. Snippet by Outsourcing Model
2.8. Snippet by End-User
2.9. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Expanding Biologics Pipeline
3.1.1.2. CDMO Strategy & Expansion
3.1.2. Restraints
3.1.2.1. Supply-chain/Geopolitical Risks
3.1.2.2. Regulatory & Compliance Complexity
3.1.3. Opportunity
3.1.3.1. Biosimilars Manufacturing Services
3.1.3.2. Regional Expansion
3.1.4. Impact Analysis
4. GLOBAL BIOLOGICS OUTSOURCING MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY SERVICE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
5.1.2. Market Attractiveness Index, By Service Type
5.2. Process Development*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Cell Development
5.4. Analytical Services
5.5. Others
6. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY PRODUCT
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
6.1.2. Market Attractiveness Index, By Product
6.2. Antibodies*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Vaccines
6.4. Cell and Gene Therapies
6.5. Recombinant Proteins
6.6. Others
7. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY PROCESS STAGE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
7.1.2. Market Attractiveness Index, By Process Stage
7.2. Clinical*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Phase I
7.2.4. Phase II
7.2.5. Phase III
7.3. Commercial
7.4. Research
8. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY SOURCE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
8.1.2. Market Attractiveness Index, By Source
8.2. Mammalian*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Microorganisms
9. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY OUTSOURCING MODEL
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
9.1.2. Market Attractiveness Index, By Outsourcing Model
9.2. CDMO*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. CMO
9.4. CRO
10. GLOBAL BIOLOGICS OUTSOURCING MARKET: BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Biotech Companies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Pharmaceutical Companies
10.4. Research Organizations
10.5. Others
11. GLOBAL BIOLOGICS OUTSOURCING MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.9.1. U.S.
11.2.9.2. Canada
11.2.9.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.9.1. Germany
11.3.9.2. U.K.
11.3.9.3. France
11.3.9.4. Spain
11.3.9.5. Italy
11.3.9.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.9.1. Brazil
11.4.9.2. Argentina
11.4.9.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.9.1. China
11.5.9.2. India
11.5.9.3. Japan
11.5.9.4. South Korea
11.5.9.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process Stage
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Outsourcing Model
11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
12.1. Competitive Overview and Key Market Players
12.2. Market Share Analysis and Positioning Matrix
12.3. Strategic Partnerships, Mergers & Acquisitions
12.4. Key Developments in Product Portfolios and Innovations
12.5. Company Benchmarking
13. COMPANY PROFILES
13.1. AbbVie Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.2.1. Product Description
13.1.2.2. Product Key Performance Indicators (KPIs)
13.1.2.3. Historic and Forecasted Product Sales
13.1.2.4. Product Sales Volume
13.1.3. Financial Overview
13.1.3.1. Company Revenue
13.1.3.2. Geographical Revenue Shares
13.1.3.3. Revenue Forecasts
13.1.4. Key Developments
13.1.4.1. Mergers & Acquisitions
13.1.4.2. Key Product Development Activities
13.1.4.3. Regulatory Approvals, etc.
13.1.4.4. SWOT Analysis
13.2. Boehringer Ingelheim International GmbH
13.3. Catalent, Inc
13.4. Charles River Laboratories
13.5. WuXi Biologics
13.6. CordenPharma
13.7. Rentschler Biopharma SE
13.8. Syngene International Limited (LIST NOT EXHAUSTIVE)
14. ASSUMPTIONS AND RESEARCH METHODOLOGY
14.1. Data Collection Methods
14.2. Data Triangulation
14.3. Forecasting Techniques
14.4. Data Verification and Validation
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
LIST OF TABLES
Table 1 Global Biologics Outsourcing Market Value, By Service Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Biologics Outsourcing Market Value, By Product, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Biologics Outsourcing Market Value, By Process Stage, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Biologics Outsourcing Market Value, By Source, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Biologics Outsourcing Market Value, By Outsourcing Model, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Biologics Outsourcing Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Biologics Outsourcing Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Biologics Outsourcing Market Value, By Service Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 10 Global Biologics Outsourcing Market Value, By Product, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 12 Global Biologics Outsourcing Market Value, By Process Stage, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 14 Global Biologics Outsourcing Market Value, By Source, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 16 Global Biologics Outsourcing Market Value, By Outsourcing Model, 2025, 2029 & 2033 (US$ Billion)
Table 17 Global Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 18 Global Biologics Outsourcing Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 19 Global Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Global Biologics Outsourcing Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 21 Global Biologics Outsourcing Market Value, By Region, 2022-2033 (US$ Billion)
Table 22 North America Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 23 North America Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 24 North America Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 25 North America Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 26 North America Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 27 North America Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 North America Biologics Outsourcing Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Biologics Outsourcing Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Europe Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 37 Europe Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 38 Europe Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 39 Europe Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 40 Europe Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 41 Europe Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 42 Europe Biologics Outsourcing Market Value, By Country, 2022-2033 (US$ Billion)
Table 43 South America Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 44 South America Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 45 South America Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 46 South America Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 47 South America Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 48 South America Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 49 South America Biologics Outsourcing Market Value, By Country, 2022-2033 (US$ Billion)
Table 50 Middle East and Africa Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 51 Middle East and Africa Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 52 Middle East and Africa Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 53 Middle East and Africa Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 54 Middle East and Africa Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 55 Middle East and Africa Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 56 Middle East and Africa Biologics Outsourcing Market Value, By Country, 2022-2033 (US$ Billion)
Table 57 AbbVie Inc.: Overview
Table 58 AbbVie Inc.: Product Portfolio
Table 59 AbbVie Inc.: Key Developments
Table 60 Boehringer Ingelheim International GmbH: Overview
Table 61 Boehringer Ingelheim International GmbH: Product Portfolio
Table 62 Boehringer Ingelheim International GmbH: Key Developments
Table 63 Catalent, Inc: Overview
Table 64 Catalent, Inc: Product Portfolio
Table 65 Catalent, Inc: Key Developments
Table 66 Charles River Laboratories: Overview
Table 67 Charles River Laboratories: Product Portfolio
Table 68 Charles River Laboratories: Key Developments
Table 69 WuXi Biologics: Overview
Table 70 WuXi Biologics: Product Portfolio
Table 71 WuXi Biologics: Key Developments
Table 72 CordenPharma: Overview
Table 73 CordenPharma: Product Portfolio
Table 74 CordenPharma: Key Developments
Table 75 Rentschler Biopharma SE: Overview
Table 76 Rentschler Biopharma SE: Product Portfolio
Table 77 Rentschler Biopharma SE: Key Developments
Table 78 Syngene International Limited: Overview
Table 79 Syngene International Limited: Product Portfolio
Table 80 Syngene International Limited: Key Developments
Table 1 Global Biologics Outsourcing Market Value, By Service Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Biologics Outsourcing Market Value, By Product, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Biologics Outsourcing Market Value, By Process Stage, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Biologics Outsourcing Market Value, By Source, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Biologics Outsourcing Market Value, By Outsourcing Model, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Biologics Outsourcing Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Biologics Outsourcing Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Biologics Outsourcing Market Value, By Service Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 10 Global Biologics Outsourcing Market Value, By Product, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 12 Global Biologics Outsourcing Market Value, By Process Stage, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 14 Global Biologics Outsourcing Market Value, By Source, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 16 Global Biologics Outsourcing Market Value, By Outsourcing Model, 2025, 2029 & 2033 (US$ Billion)
Table 17 Global Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 18 Global Biologics Outsourcing Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 19 Global Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Global Biologics Outsourcing Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 21 Global Biologics Outsourcing Market Value, By Region, 2022-2033 (US$ Billion)
Table 22 North America Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 23 North America Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 24 North America Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 25 North America Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 26 North America Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 27 North America Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 North America Biologics Outsourcing Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Biologics Outsourcing Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Europe Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 37 Europe Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 38 Europe Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 39 Europe Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 40 Europe Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 41 Europe Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 42 Europe Biologics Outsourcing Market Value, By Country, 2022-2033 (US$ Billion)
Table 43 South America Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 44 South America Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 45 South America Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 46 South America Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 47 South America Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 48 South America Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 49 South America Biologics Outsourcing Market Value, By Country, 2022-2033 (US$ Billion)
Table 50 Middle East and Africa Biologics Outsourcing Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 51 Middle East and Africa Biologics Outsourcing Market Value, By Product, 2022-2033 (US$ Billion)
Table 52 Middle East and Africa Biologics Outsourcing Market Value, By Process Stage, 2022-2033 (US$ Billion)
Table 53 Middle East and Africa Biologics Outsourcing Market Value, By Source, 2022-2033 (US$ Billion)
Table 54 Middle East and Africa Biologics Outsourcing Market Value, By Outsourcing Model, 2022-2033 (US$ Billion)
Table 55 Middle East and Africa Biologics Outsourcing Market Value, By End-User, 2022-2033 (US$ Billion)
Table 56 Middle East and Africa Biologics Outsourcing Market Value, By Country, 2022-2033 (US$ Billion)
Table 57 AbbVie Inc.: Overview
Table 58 AbbVie Inc.: Product Portfolio
Table 59 AbbVie Inc.: Key Developments
Table 60 Boehringer Ingelheim International GmbH: Overview
Table 61 Boehringer Ingelheim International GmbH: Product Portfolio
Table 62 Boehringer Ingelheim International GmbH: Key Developments
Table 63 Catalent, Inc: Overview
Table 64 Catalent, Inc: Product Portfolio
Table 65 Catalent, Inc: Key Developments
Table 66 Charles River Laboratories: Overview
Table 67 Charles River Laboratories: Product Portfolio
Table 68 Charles River Laboratories: Key Developments
Table 69 WuXi Biologics: Overview
Table 70 WuXi Biologics: Product Portfolio
Table 71 WuXi Biologics: Key Developments
Table 72 CordenPharma: Overview
Table 73 CordenPharma: Product Portfolio
Table 74 CordenPharma: Key Developments
Table 75 Rentschler Biopharma SE: Overview
Table 76 Rentschler Biopharma SE: Product Portfolio
Table 77 Rentschler Biopharma SE: Key Developments
Table 78 Syngene International Limited: Overview
Table 79 Syngene International Limited: Product Portfolio
Table 80 Syngene International Limited: Key Developments
LIST OF FIGURES
Figure 1 Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 3 Global Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 4 Global Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 5 Global Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 6 Global Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 7 Global Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 8 Global Biologics Outsourcing Market Share, By Region, 2024 & 2033 (%)
Figure 9 Global Biologics Outsourcing Market Y-o-Y Growth, By Service Type, 2023-2033 (%)
Figure 10 Process Development Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 11 Cell Development Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 12 Analytical Services Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 13 Others Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 14 Global Biologics Outsourcing Market Y-o-Y Growth, By Product, 2023-2033 (%)
Figure 15 Antibodies Product in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 16 Vaccines Product in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 17 Cell and Gene Therapies Product in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 18 Recombinant Proteins Product in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 19 Others Product in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Biologics Outsourcing Market Y-o-Y Growth, By Process Stage, 2023-2033 (%)
Figure 21 Clinical Process Stage in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 22 Commercial Process Stage in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 23 Research Process Stage in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Biologics Outsourcing Market Y-o-Y Growth, By Source, 2023-2033 (%)
Figure 25 Mammalian Source in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 26 Microorganisms Source in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 27 Global Biologics Outsourcing Market Y-o-Y Growth, By Outsourcing Model, 2023-2033 (%)
Figure 28 CDMO Outsourcing Model in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 29 CMO Outsourcing Model in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 30 CRO Outsourcing Model in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 31 Global Biologics Outsourcing Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 32 Biotech Companies End-User in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 33 Research Organizations End-User in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 34 Others End-User in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 35 Global Biologics Outsourcing Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 36 North America Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 37 North America Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 38 North America Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 39 North America Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 40 North America Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 41 North America Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 42 North America Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 43 North America Biologics Outsourcing Market Share, By Country, 2024 & 2033 (%)
Figure 44 Asia-Pacific Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 45 Asia-Pacific Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 46 Asia-Pacific Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 47 Asia-Pacific Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 48 Asia-Pacific Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 49 Asia-Pacific Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 50 Asia-Pacific Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 51 Asia-Pacific Biologics Outsourcing Market Share, By Country, 2024 & 2033 (%)
Figure 52 Europe Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 53 Europe Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 54 Europe Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 55 Europe Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 56 Europe Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 57 Europe Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 58 Europe Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 59 Europe Biologics Outsourcing Market Share, By Country, 2024 & 2033 (%)
Figure 60 South America Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 61 South America Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 62 South America Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 63 South America Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 64 South America Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 65 South America Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 66 South America Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 67 South America Biologics Outsourcing Market Share, By Country, 2024 & 2033 (%)
Figure 68 Middle East and Africa Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 69 Middle East and Africa Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 70 Middle East and Africa Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 71 Middle East and Africa Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 72 Middle East and Africa Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 73 Middle East and Africa Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 74 Middle East and Africa Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 75 AbbVie Inc.: Financials
Figure 76 Boehringer Ingelheim International GmbH: Financials
Figure 77 Catalent, Inc: Financials
Figure 78 Charles River Laboratories: Financials
Figure 79 WuXi Biologics: Financials
Figure 80 CordenPharma: Financials
Figure 81 Rentschler Biopharma SE: Financials
Figure 82 Syngene International Limited: Financials
Figure 1 Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 3 Global Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 4 Global Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 5 Global Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 6 Global Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 7 Global Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 8 Global Biologics Outsourcing Market Share, By Region, 2024 & 2033 (%)
Figure 9 Global Biologics Outsourcing Market Y-o-Y Growth, By Service Type, 2023-2033 (%)
Figure 10 Process Development Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 11 Cell Development Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 12 Analytical Services Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 13 Others Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 14 Global Biologics Outsourcing Market Y-o-Y Growth, By Product, 2023-2033 (%)
Figure 15 Antibodies Product in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 16 Vaccines Product in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 17 Cell and Gene Therapies Product in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 18 Recombinant Proteins Product in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 19 Others Product in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Biologics Outsourcing Market Y-o-Y Growth, By Process Stage, 2023-2033 (%)
Figure 21 Clinical Process Stage in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 22 Commercial Process Stage in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 23 Research Process Stage in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Biologics Outsourcing Market Y-o-Y Growth, By Source, 2023-2033 (%)
Figure 25 Mammalian Source in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 26 Microorganisms Source in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 27 Global Biologics Outsourcing Market Y-o-Y Growth, By Outsourcing Model, 2023-2033 (%)
Figure 28 CDMO Outsourcing Model in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 29 CMO Outsourcing Model in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 30 CRO Outsourcing Model in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 31 Global Biologics Outsourcing Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 32 Biotech Companies End-User in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 33 Research Organizations End-User in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 34 Others End-User in Global Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 35 Global Biologics Outsourcing Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 36 North America Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 37 North America Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 38 North America Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 39 North America Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 40 North America Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 41 North America Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 42 North America Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 43 North America Biologics Outsourcing Market Share, By Country, 2024 & 2033 (%)
Figure 44 Asia-Pacific Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 45 Asia-Pacific Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 46 Asia-Pacific Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 47 Asia-Pacific Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 48 Asia-Pacific Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 49 Asia-Pacific Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 50 Asia-Pacific Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 51 Asia-Pacific Biologics Outsourcing Market Share, By Country, 2024 & 2033 (%)
Figure 52 Europe Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 53 Europe Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 54 Europe Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 55 Europe Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 56 Europe Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 57 Europe Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 58 Europe Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 59 Europe Biologics Outsourcing Market Share, By Country, 2024 & 2033 (%)
Figure 60 South America Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 61 South America Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 62 South America Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 63 South America Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 64 South America Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 65 South America Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 66 South America Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 67 South America Biologics Outsourcing Market Share, By Country, 2024 & 2033 (%)
Figure 68 Middle East and Africa Biologics Outsourcing Market Value, 2022-2033 (US$ Billion)
Figure 69 Middle East and Africa Biologics Outsourcing Market Share, By Service Type, 2024 & 2033 (%)
Figure 70 Middle East and Africa Biologics Outsourcing Market Share, By Product, 2024 & 2033 (%)
Figure 71 Middle East and Africa Biologics Outsourcing Market Share, By Process Stage, 2024 & 2033 (%)
Figure 72 Middle East and Africa Biologics Outsourcing Market Share, By Source, 2024 & 2033 (%)
Figure 73 Middle East and Africa Biologics Outsourcing Market Share, By Outsourcing Model, 2024 & 2033 (%)
Figure 74 Middle East and Africa Biologics Outsourcing Market Share, By End-User, 2024 & 2033 (%)
Figure 75 AbbVie Inc.: Financials
Figure 76 Boehringer Ingelheim International GmbH: Financials
Figure 77 Catalent, Inc: Financials
Figure 78 Charles River Laboratories: Financials
Figure 79 WuXi Biologics: Financials
Figure 80 CordenPharma: Financials
Figure 81 Rentschler Biopharma SE: Financials
Figure 82 Syngene International Limited: Financials
